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Background: Regulation of human airway smooth muscle cells (HASMC) by cytokines contributes to chemotactic
factor levels and thus to inflammatory cell accumulation in lung diseases. Cytokines such as the gp130 family
member Oncostatin M (OSM) can act synergistically with Th2 cytokines (IL-4 and IL-13) to modulate lung cells,
however whether IL-17A responses by HASMC can be altered is not known.
Objective: To determine the effects of recombinant OSM, or other gp130 cytokines (LIF, IL-31, and IL-6) in regulating
HASMC responses to IL-17A, assessing MCP-1/CCL2 and IL-6 expression and cell signaling pathways.
Methods: Cell responses of primary HASMC cultures were measured by the assessment of protein levels in
supernatants (ELISA) and mRNA levels (qRT-PCR) in cell extracts. Activation of STAT, MAPK (p38) and Akt pathways were
measured by immunoblot. Pharmacological agents were used to assess the effects of inhibition of these pathways.
Results: OSM but not LIF, IL-31 or IL-6 could induce detectable responses in HASMC, elevating MCP-1/CCL2, IL-6 levels
and activation of STAT-1, 3, 5, p38 and Akt cell signaling pathways. OSM induced synergistic action with IL-17A
enhancing MCP-1/CCL-2 and IL-6 mRNA and protein expression, but not eotaxin-1 expression, while OSM in
combination with IL-4 or IL-13 synergistically induced eotaxin-1 and MCP-1/CCL2. OSM elevated steady state mRNA
levels of IL-4Rα, OSMRβ and gp130, but not IL-17RA or IL-17RC. Pharmacologic inhibition of STAT3 activation using
Stattic down-regulated OSM, OSM/IL-4 or OSM/IL-13, and OSM/IL-17A synergistic responses of MCP-1/CCL-2 induction,
whereas, inhibitors of Akt and p38 MAPK resulted in less reduction in MCP-1/CCL2 levels. IL-6 expression was more
sensitive to inhibition of p38 (using SB203580) and was affected by Stattic in response to IL-17A/OSM stimulation.
Conclusions: Oncostatin M can regulate HASMC responses alone or in synergy with IL-17A. OSM/IL-17A combinations
enhance MCP-1/CCL2 and IL-6 but not eotaxin-1. Thus, OSM through STAT3 activation of HASMC may participate in
inflammatory cell recruitment in inflammatory airway disease.
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Allergic asthma involves complex inflammatory path-
ways that manifest symptoms and pathology that are
generally accepted to be influenced by functions of Th2
cells and their products including IL-4, IL-5 and IL-13
[1-3]. These contribute to mechanisms of immune cell* Correspondence: richards@mcmaster.ca
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unless otherwise stated.accumulation, alterations in airway hyper-responsiveness,
excess mucus secretion and increased extracellular deposi-
tion around airways [4-7]. Activation of stromal or struc-
tural cells such as fibroblasts and airway smooth muscle
cells contribute to the process [8,9]. These cells can be reg-
ulated by a variety of small molecular weight mediators,
growth factors and cytokines to contract and/or to release
molecules that further influence inflammation and matrix
remodeling. Indeed, the production of cytokines by stromal
cells (fibroblasts, epithelial cells and smooth muscle cells)
could contribute significantly to the load of a chemo-
kine such as MCP-1/CCL-2. These chemokines can at-
tract monocytes/lymphocytes and fibrocytes [10,11] thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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accumulation. Eotaxin-1 has also been recently shown to
stimulate fibrocyte chemotaxis [12] and can be released
from human airway smooth muscle cells (HASMC) in vitro
upon IL-1 or TNF stimulation [13]. HASMC can respond
directly to Th2 cytokines [14,15] and with synergy in re-
sponse to Th2 cytokine and IL-1 combinations [16]. More
recently, the role of Th17 cells has become prominent in
paradigms of T-helper cell subsets that include Th17, Th1,
Th2 and regulatory T cells. IL-17A is the most character-
ized of the IL-17 family of cytokines (IL-17A through
IL-17 F) that also play roles in inflammation, T cell re-
sponses and autoimmunity as previously reviewed [17,18].
IL-17A interacts with a receptor complex of IL-17RA/IL-
17RC, which is generally expressed on a wide variety of cell
types [18]. IL-17A has been detected in asthmatic subjects
and been shown to regulate lung fibroblasts [19], epithelial
cells[20]and functions of airway smooth muscle cells
including chemokine release [21-23],proliferation [24]
and contraction [25].
In addition to typical Th2 and Th17 derived cytokines,
several sets of studies have implicated the involvement
of certain members of the gp130 cytokine family, such
as IL-6, and IL-11 (reviewed in [26,27]) in inflammatory
airway diseases. The gp130 cytokines include IL-6, IL-11,
CT-1, LIF, Oncostatin M (OSM) and IL-31 among others,
and are grouped together generally on the basis of their
utilization of receptor complexes that require the gp130
signaling chain (with the exception of IL-31). Various
family members can function in inflammation, immun-
ity, hematopoiesis, cell differentiation and the regula-
tion of extracellular matrix [28-31]. Among this group,
OSM has been demonstrated to regulate stromal cell
expression of cytokines and extracellular matrix modu-
lators and have been found to be elevated in chronic con-
ditions such as arthritis [32,33] and psoriasis [34,35]. In
addition, evidence indicates elevated levels of OSM in air-
way inflammation [36-38] and severe asthma [39], where
potential roles may involve effects on various structural
cells including lung fibroblasts [40], airway epithelial cells
[41-43] and airway smooth muscle cells [36,37,44]. Reports
have described synergy with OSM /IL-4 combination in in-
ducing eotaxin-1, and OSM/IL-1 combination in inducing
VEGF [36,37] expression by HASMC in vitro. Here, we
assess OSM modulation of IL-17A responses in context of
activities of LIF, IL-31, IL-6 and IL-11 in vitro. We observe
that OSM, but not LIF, IL-31 or other gp130 cytokines, can
synergize with IL-17A, IL-4 or IL-13 in chemokine induc-
tion, correlating with STAT-3 signaling but not receptor
chain alterations. The results indicate that OSM functions
in sensitizing HASMC to the presence of Th17 cytokines
as well as inflammatory and Th2 cytokines, suggesting an
expanded role in exacerbation of airway inflammation in
human disease.Methods
Cell cultures and stimulation
Cultures of human airway smooth muscle cells (HASMC)
were generated from airways obtained from lung cancer
patients (ex–smokers, five diagnosed with COPD and 2
with no other conditions) undergoing thoracic surgery
at St Joseph’s Healthcare Hamilton after obtaining their in-
formed consent and with the approval of the local Research
Ethics Board (approval RP#00-1839). Smooth muscle cells
were isolated from disease-free areas of the airways and
expanded in RPMI supplemented with 10% fetal bovine
serum (FBS) and 1% L-Glutamine for up to 8 passages as
previously described [45]. For analysis of cytokine synthesis,
HASMC were plated at a cell density of 10,000- 20,000 cells
per well in 24-well or 96-well tissue culture plates and incu-
bated overnight. Cells were washed with phosphate-
buffered saline (PBS) and incubated for 3 hours with
fresh media containing 2% FBS. Cells were then stimulated
with the indicated cytokines in 2% FBS containing media,
and 18–24 hour supernatants were later collected and
stored for future analysis by ELISA. Recombinant human
cytokines, (OSM, LIF, IL-31, IL-11, IL-6, IL-17A, IL-4,
IL-13 and IFNγ, azide-free) were purchased from R&D
systems (Cedarlane, Burlington, Canada). The STAT-3 in-
hibitor, Stattic, was purchased from Abcam Biochemical
(Toronto, Canada) and used at the indicated concentra-
tions applied for 30 minutes before stimulation with cyto-
kines. The p38 inhibitor (SB203580) and Akt inhibitor
(Akt X) were purchased from Calbiochem (San Diego, CA).
Cells were pre-treated for 1 hour prior to cytokine
stimulation with 10 uM SB203580 or 5 uM Akt X inhibitor.
Enzyme-linked Immunosorbent Assay (ELISA)
Levels of cytokines in the cell culture supernatants were
quantified by ELISA using Duoset antibody pairs for IL-6
and eotaxin-1 purchased from R&D Systems Inc and
MCP-1/CCL-2, purchased from Biolegend (San Diego,
CA), used as per manufacturer’s protocols. Limit of
detection of each ELISA was 15 pg/ml or less.
RNA extraction and real-time PCR
For RNA analysis, confluent HASMC in T75 culture flasks
were washed with phosphate-buffered saline (PBS) and in-
cubated for 3 hours with fresh RPMI media containing 2%
FBS. Cells were then washed again and stimulated with
fresh medium (2% FBS/RPMI) with the indicated cytokines
for 6 or 18 hours. Total RNA was prepared as per manu-
facturer’s protocols using PureLink RNA Mini kits (Life
Technologies, Burlington, Canada), and then analyzed by
quantitative real-time PCR (TaqMan) using predetermined
assay reagents (PDAR) purchased from Life Technologies
(Burlington, Canada) for MCP-1/CCL-2, IL-6, eotaxin-1,
eotaxin-3, IL-8, IL-17RA, IL-17RC, IL-4Rα, gp130/IL-6ST
and OSMRβ.
Kwofie et al. Respiratory Research  (2015) 16:14 Page 3 of 14Immunoblots
HASMC were plated at a cell density of 90,000 cells per
well in 6-well costars and incubated overnight. Cells were
washed with PBS, and incubated for 3 hours in RPMI
media containing 2% FBS. Cells were then stimulated in
fresh 2% FBS/RPMI containing indicated cytokines for
20 minutes. Cells were then lysed in 200 μL of ice cold
RIPA buffer containing protease inhibitors and sheared
by passing the cells through a 21-gauge needle 5 times.
Protein concentrations of total cell lysates were deter-
mined using Bradford assays (Bio-Rad) and denatured
by boiling in SDS-containing reducing buffer. 15 μg of total
protein were separated by 8% SDS-PAGE and transferred
to a nitrocellulose membrane by standard methods. Blots
were blocked for 1 hour at room temperature using Licor
odyssey blocking buffer (Mandal, Guelph, Canada) and
were then probed for the indicated phosphorylated or
non-phosphorylated proteins, as indicated in figures, at
4°C overnight. Primary antibodies specific for p-Y-STAT-1,
STAT 1, p-Y-STAT3, STAT3, p-Y STAT5, STAT5, p-Y-
STAT6, pT/Y-p38, p38, p-T/Y-JNK, p-S-Akt, and Akt
were purchased from Cell Signaling Technology (New
England Biolabs Ltd., Canada). Primary antibodies specific
for Actin and STAT6 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Primary antibodies were
diluted 1:1000 in odyssey buffer and were detected using
Licor anti-Rabbit or anti-Goat IRDye infrared secondary
antibodies at 1:5000 dilution (Mandal), and imaged using a
Licor odyssey infrared scanner (Mandal).
Statistical analysis
GraphPad Prism version 5.0 for Macs (GraphPad Soft-
ware, San Diego, CA) was used for generating graphs
and statistical analyses. Figures represent mean values ±
standard deviation (SD). The student’s one-tailed t test,
One- or Two-Way analysis of variance (ANOVA) with
Tukey or Bonferroni post-tests were used to assess stati-
stical differences between means; where values of p < 0.05
were considered statistically significant.
Results
Regulation of HASMC by OSM and IL-17A
We first examined the response of HASMC to recombin-
ant OSM in the regulation of MCP-1/CCL-2 and IL-6
using ELISA systems for protein analysis. We observed a
dose-responsive induction of MCP-1/CCL-2 (Figure 1A,
left panel), detectable at 0.5 ng/ml and further elevated
at higher concentrations of OSM. When stimulating
HASMC cultures with IL-6, LIF or IL-31, at concentra-
tions ranging up to 50 ng/ml, we did not observe detect-
able changes in MCP-1/CCL-2 supernatant levels. OSM
stimulation also elevated IL-6 in supernatants of HASMC
(Figure 1A, right panel), while we did not detect any
changes in IL-6 upon stimulation with LIF or IL-31 in thissystem. To assess the effects of IL-17A in regulation of
HASMC, we cultured cells with increasing doses of IL-17A
(Figure 1B and C). We observed minimal responses to
doses of IL-17A tested alone (0.1 to 10 ng/ml) when
measuring IL-6 or MCP-1 levels in supernatants. How-
ever, we were able to detect synergistic induction of IL-6
(Figure 1B) and MCP-1 (Figure 1C) levels in supernatants
upon co-stimulation with 10 ng/ml OSM and IL-17A.
This was consistently evident in different HASMC cell
lines examined, albeit the magnitude of responses varied
somewhat between cell lines. Baseline levels of MCP-1
(approximate mean of 170 ug/ml, Figure 1C and 175 ug/
ml in Figure 2A) were not statistically altered by stimula-
tion with 10 ng/ml IL-17A (approximate mean of 225 ug/
ml in Figure 1C and 235 ug/ml in Figure 2A). To deter-
mine whether lower concentrations of OSM could induce
synergy with IL-17A, we cultured cells with increasing
doses of IL-17A in the presence of 0, 0.1, 1 or 10 ng/ml
OSM. Levels of MCP-1/CCL-2 (Figure 2A, left panel) and
IL-6 (Figure 2A, right panel) showed that addition of
OSM at 1 or 10 ng/ml could induce significant increases
in MCP-1/CCL-2 or IL-6 responses to IL-17A.
We next assessed whether OSM could synergize with
typical Th1 (IFNγ) or Th2 (IL-4, IL-13) cytokines in the
regulation of MCP-1/CCL-2 by HASMC. Figure 2B and
C show that OSM (0.5 ng/ml) co-stimulation with IL-4
or IL-13 resulted in synergistic increases in MCP-1/
CCL-2 (left panels) and IL-6 levels were also elevated
upon co-stimulation (right panels). On the other hand,
OSM and IFNγ co-stimulations did not result in MCP-1/
CCL-2 or IL-6 modulation differently than either cytokine
alone (Figure 2D left and right panels). In the assessment
of eotaxin-3 mRNA (Additional file 1: Figure S2), the
function of OSM or IL-17A was negligible in comparison
to that of IL-4 or IL-13. This is in contrast to IL-8
responses, which showed marked up-regulation by OSM/
IL-17A combinations and not by IL-4/OSM or IL-13/OSM
(Additional file 1: Figure S3).
Regulation of HASMC by other gp130 cytokines
The gp130 cytokine family shares several biological func-
tions, mediated through gp130 signaling, in cells that ex-
press the specific ligand receptor chains. We thus assessed
whether LIF (utilizes the complex of gp130 and LIFRα),
IL-31 (utilizes the complex of IL-31R and OSMRβ chain),
or other members of the gp130 cytokine family could regu-
late HASMC expression of MCP-1/CCL-2 in context of
IL-4, IL-13 or IL-17A co-stimulation (Figure 3). MCP-1/
CCL-2 levels (Figure 3A) were synergistically induced by
the combination of OSM with IL-17A, IL-4 or IL-13. IL-6
levels (Figure 3B) were most pronounced with OSM and
IL-17A combinations. Eotaxin-1 levels were induced syner-
gistically by OSM in combination with IL-4 or IL-13, but
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Figure 1 HASMC responses to OSM and IL-17A. HASMC were cultured and prepared for stimulation as described in methods, where each
treatment is completed in quadruplicates within each cell line. Cells were then stimulated in medium supplemented with 2% FBS and 0–50 ng/ml
of the indicated gp130 cytokines. Protein concentrations in 24-hour supernatants were determined by ELISA for (A) MCP-1/CCL-2 (Left panel) and IL-6
(Right panel). *p < 0.05; ***p < 0.001 indicates statistical significance compared to no treatment as well as other indicated cytokines using One-Way
ANOVA with Bonferroni’s post-test. Panel (B) (IL-6) and (C) (MCP-1) shows 24-hour supernatants from independent cell lines derived from 5 patients,
prepared as above and stimulated with the indicated amounts of OSM, IL-17A or the combination as indicated. **p < 0.01 comparing indicated
cytokines combinations to either cytokine alone using One-Way ANOVA with Bonferroni’s post-test.
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Figure 3A-C, showed no effects in the modulation of
MCP-1/CCL-2, IL-6, or eotaxin-1 in this system alone or
in combination with IL-17A, nor did IL-11 or IL-6 (shownin Additional file 1: Figure S1). In testing the effects of
stimulation in serum-free conditions (2 days quiesed in
RPMI/1%BSA before stimulation), the response to OSM or
IL-17A, and the OSM/IL-17A combination, was identical
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Figure 2 OSM stimulation with IL-17A, IL-4 or IL-13 induces MCP-1/CCL2 and IL-6. HASMC cultures were prepared and stimulated as in
Figure 1 with the indicated cytokines (in quadruplicates) and concentrations of: (A) IL-17A up to 10 ng/ml and in combination with 0, 0.01, 0.1, 1,
and 10 ng/ml OSM, (B) IL-4 at 0 to 10 ng/ml and in combination with 0 or 0.5 ng/ml OSM, (C) IL-13 at 0 to 10 ng/ml and in combination with 0
or 0.5 ng/ml OSM, (D) IFNγ at 0 to 10 ng/ml and in combination with 0 or 0.5 ng/ml OSM. Data shown are from one of two individual cell lines
that showed identical trends. 24-hour supernatants were collected and cytokine concentrations were quantified by ELISA for MCP-1/CCL-2
(left panels) or IL-6 (right panels). *p < 0.05; **p < 0.01; ***p < 0.001 comparing indicated cytokine combinations to either cytokine alone using
Two-Way ANOVA with Bonferroni’s post-test.
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the cell supernatants (Additional file 1: Figure S4 A, B),
although we observed lower absolute quantities than the 2%
FBS/RPMI conditions. We also observed identical trends
with IL-4, OSM and IL-4/OSM regulation of eotaxin-1 in
the same serum-free culture conditions (Additional file 1:
Figure S4C) compared to 2% FBS conditions.
Since activation of the JAK-STAT signaling cascade is a
prominent intracellular signaling pathway in response togp130 cytokines, we assessed levels of tyr-phosphorylated
STAT1, STAT3, STAT5 and STAT6 in HASMC lysates
after cytokine stimulation (Figure 3D) as well as MAPK
(p38 and JNK) and Akt pathway activation by standard
immunoblots (Figure 3D). Quantitative assessment of
band intensities through densitometry (Figure 3E) show
that signals for P-STAT-1, 3 and 5 were upregulated by
OSM but not by the other members of the gp130 cytokines
tested in these cells. Signals for p-(T/Y)-JNK, p-(T/Y)-p38
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Figure 3 (See legend on next page.)
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Figure 3 OSM and other gp130 cytokine stimulation and HASMC responses. (A-C) HASMC cultures were prepared and stimulated as in
Figure 1 with the indicated cytokines and concentrations of 10 ng/ml for each. Data shown are from one of two individual cell lines that showed
identical trends. 24-hour culture supernatants were assessed by ELISA for levels of MCP-1/CCL-2 (A), IL-6 (B) and eotaxin-1 (C). ***p < 0.001
indicates statistical significance comparing indicated cytokine combinations to either cytokine alone using One-Way ANOVA with Bonferroni’s post-test.
(D) HASMC cultures were stimulated with OSM, LIF, IL-11, IL-31 or IL-6 (10 ng/ml) for 20 minutes and cell lysates were prepared for immunoblots as
described in methods. The lysates were probed for p-Y-STAT1, STAT1, p-Y-STAT3, STAT3, p-Y- STAT5, STAT5, p-Y-STAT6, p-Ser-Akt, p-T/Y-p38,
p-T/Y-JNK and Actin as indicated. (E) Quantitative analysis of band intensity using densitometry (ImageJ) corrected to Actin or total protein for
each probe and expressed as fold change relative to control (unstimulated).
Kwofie et al. Respiratory Research  (2015) 16:14 Page 7 of 14and p-(S)-Akt were also upregulated by OSM, but minimal
or no signals were observed upon stimulation with the
other gp130 cytokines tested in these cells. This was con-
sistent in two separate cell lines examined. We also ob-
served that the regulation of STAT3 and p38 cell signaling
(phosphorylation) in serum-free conditions were also iden-
tical in trend (Additional file 1: Figure S5) to that in 2%
FBS/RPMI conditions. OSM-induced signals were evi-
dent and other gp130 cytokine signals were low/absent,
although again, the levels of signals were much lower in
serum free (RPMI/ 1% BSA) conditions.Regulation of mRNA levels by OSM in HASMC
To assess whether the regulation of the protein was
linked to mRNA regulation, we measured mRNA levels in
HASMC after stimulation with OSM, IL-4, IL-13 and IL-
17A at both 6 hours (Figure 4A) and at 18 hours (Figure 4B).
Changes in levels of mRNA reflected trends seen in the pro-
tein levels. OSM and IL-17A co-stimulation synergistically
regulated MCP-1, IL-6 and IL-8, but not eotaxin-1 mRNA
(Figure 4). OSM with either IL-4 or IL-13 synergized to
induce MCP-1, IL-6 and eotaxin-1 but not IL-8 mRNA
(Figure 4). Although eotaxin-3 mRNA was regulated by IL-
4 or IL-13 (Additional file 1: Figure S2), we did not observe
eotaxin-3 regulation by IL-17A, OSM, or the combinations.
Furthermore, we were not able to detect eotaxin-3 in
HASMC culture supernatants by ELISA (data not shown).
Since the regulation of receptor expression may influ-
ence responses by HASMC, we assessed the mRNA ex-
pression of receptor chains IL-17RA, IL-17RC, gp130,
OSMRβ and IL-4Rα (Figure 5). OSM did not alter levels
of IL-17RA or IL-17RC mRNA at 6 hours. Both IL-4 and
IL-13 enhanced IL-17RA levels (over 4-fold and 2-fold, re-
spectively) but did not regulate OSMRβ mRNA. OSM
stimulation for 6 hours resulted in induction of mRNA
levels for IL-4Rα 2.5-3 fold, and its own receptor chains
OSMRβ and gp130 (approximately 4 fold and 2.3-fold,
respectively). These altered levels showed the same trend
at 18 hours (not shown). IL-17A stimulation did not regu-
late IL-4Rα, IL-17RA, IL-17RC, gp130 or OSMRβ, in con-
text of its marked elevation of IL-8 mRNA levels (Figure 4).Activation of cell signaling and effects of inhibitors
To determine if selective signaling pathways were amplified
with the combinations of cytokines, we assessed phosphoryl-
ation of STAT3, Akt at serine 473 and p38 by immunoblots
(Figure 6A) and quantitative densitometry for 3 different
HASMC cell lines (Figure 6B). p-(Y)-STAT3, p-(S)-Akt and
p-(T/Y)-p38 levels were up-regulated by OSM alone and in
combination with the other stimuli but not by IL-4, IL-13
and IL-17A alone in this system (Figure 6A). Levels of
STAT3 or Akt activation were not statistically different in
combination stimuli verses OSM alone in averaging the 3
cell line responses (Figure 6B, left and middle panels).
However, levels of p38 phosphorylation on average were
further increased (approx.1.7-fold, statistically significant)
with OSM/IL-17A combination stimulations of HASMC
(Figure 6B right panel). To examine whether inhibition of
these pathways could alter HASMC responses to OSM
and the synergistic responses induced by OSM combined
stimuli, we assessed HASMC responses in the presence or
absence of pharmacological inhibitors of STAT-3 (Stattic),
p38 (SB203580) and Akt (Akt X). To test the effective con-
centrations and specificity of Stattic on STAT inhibition,
1.25, 2.5 or 5 uM Stattic was used to pre-treat HASMC cell
cultures before stimulating with OSM (1 ng/ml). Levels of
phosphorylated STAT1, 3, 5, p38 and Akt were assessed by
immunoblots (Figure 6C). p-(Y)-STAT-1,3,5 signals at
20 minutes OSM stimulation were inhibited by 1.25 uM,
more so by 2.5 uM and nearly complete reduction at 5 uM
Stattic pre-incubation. Stattic is described as a STAT3
selective inhibitor [46,47] however; in our system Stattic
markedly inhibited STAT-1 and STAT-5 activation as well.
When we examined the effects of Stattic on other cell
signaling pathways MAPK (p38) and Akt, we observed
minimal reduction in p38 and Akt phosphorylation and a
lack of dose-dependent effects (Figure 6C). To assess Stattic
effects on MCP-1/CCL-2 or IL-6 production, 2.5 uM Stattic
was used to pre-treat HASMC cultures before stimulation
with the cytokines and combinations indicated (Figure 7A).
Cell viability was not altered at this concentration of the
inhibitor. Elevation of MCP-1/CCL-2 levels in response to
OSM, or the synergistic MCP-1/CCL-2 responses to OSM/
































































































































































































































































































































































































































































Figure 4 Regulation of chemokine RNA in HASMC by cytokines. HASMC were plated and prepared for RNA analysis as in methods after
6 hours (A) and 18 hours (B) of stimulation with OSM at 2 ng/ml and/or the indicated cytokines at 5 ng/ml. RNA was prepared and analyzed by
qRT-PCR using probes for the cytokines as indicated in methods. Levels are expressed as fold change relative to unstimulated (control) and
corrected to β-Actin as an endogenous reference control.
Kwofie et al. Respiratory Research  (2015) 16:14 Page 8 of 14more at 1.25 uM Stattic (not shown) and by 60% or greater
at 2.5 uM Stattic (Figure 7A left panel). In contrast, Stattic
did not alter IL-6 levels in response to the various stimuli,with the exception of the OSM/IL-17A combination
(Figure 7A, right panel). This suggests that STAT-3 has
























































































































































































Figure 5 Receptor chain mRNA levels in stimulated HASMC. HASMC were plated and prepared for RNA analysis as described in methods
after 6 hours of stimulation with the indicated cytokines at 5 ng/ml or 2 ng/ml OSM (n = 2). RNA was prepared and analyzed by qRT-PCR using
probes for the receptor subunits IL-17RA, IL-17RC, OSMRβ, gp130/IL-6ST and IL-4Rα, as indicated. Levels are expressed as fold change relative to
unstimulated (control) and corrected to β-Actin as an endogenous reference control.
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and Akt (Figure 7C) would alter cytokine responses in
HASMC. MCP-1/CCL2 levels induced by IL-17A alone or
in combination with OSM were significantly inhibited by
SB203580 at the concentration used but were not signifi-
cantly reduced in the other combinations (Figure 7B, left
panel). IL-6 levels (Figure 7B right panel) were signifi-
cantly inhibited by SB203580 regardless of the stimulation
used in HASMC cultures. The Akt X inhibitor reduced
MCP-1/CCL2 levels in supernatants of cultured HASMC
independent of the stimuli used (Figure 7C, left panel) but
did not inhibit IL-6 levels (Figure 7C, right).
Discussion
Collectively, our results indicate that OSM has a unique
function in HASMC by stimulating synergistic responsesto IL-17A in selective genes, (MCP-1/CCL-2, IL-6 and
IL-8 but not eotaxin-1). This is supported by data assessing
both the protein released on cell culture supernatants
(Figures 1, 2 and 3) and mRNA analysis (Figure 4). In
addition, the synergistic responses by OSM were not
associated with regulation of the receptor chains for
IL-17A (IL-17RA and IL-17RC), but were correlated
with the level of STAT-3 and p38 activation (Figure 3 and
Figure 7). Furthermore, related gp130 cytokine family
members LIF, IL-6, or IL-31 could not regulate such syn-
ergistic responses (Figure 3, Additional file 1: Figure S1),
indicating novel activities of OSM in the regulation of che-
mokine expression by HASMC in vitro. OSM could dose-
dependently lower the threshold to IL-17A responses with
OSM concentrations as low as 0.1 ng/ml and was clearly
evident at 1 ng/ml (Figures 1 and 2). These concentrations
A 
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'
'
Figure 6 STAT3, p38 (MAPK) and Akt activation in HASMC and effects of inhibition on HASMC responses. (A) HASMC cultures were
prepared as previously outlined for immunoblots of lysates of cells stimulated for 20 minutes with 5 ng/ml of IL-4, IL-13 and IL-17A (and/or 1 ng/ml of
OSM). Total cell lysates from 3 different cell lines were probed for p-Y-STAT3, STAT3, p-Y-STAT6, STAT6, p-S-Akt, Akt, p-T/Y-p38, and total p38 as
indicated (one representative cell line shown). (B) Quantification of band intensity using densitometry (ImageJ) corrected to total protein for
each probe and expressed as the average (3 cell lines) fold change relative to control (un-stimulated) *p <0.05 using one-tail t-test. (C). HASMC
cultures were prepared as previous for immunoblots of lysates of cells stimulated for 20 minutes with 1 ng/ml OSM, with or without pre-
incubation with 1.25, or 2.5 or 5 uM Stattic or its vehicle DMSO (Veh). The lysates were probed for p-Y-STAT1, total STAT1, p-Y-STAT3, p-Y-
STAT5, p-T/Y-p38, total p38, p-S-Akt and actin as indicated.
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of patients with severe asthma as described by Simpson
et al. [39] and indicate physiological relevance of the obser-
vations suggesting OSM regulation of HASMC function in
lung inflammation in vivo.Previous work examining HASMC responses to IL-17A
showed induction of IL-8 (CXCL-8) [21] and induction of
eotaxin-1/CCL-11 [22] through a STAT3-dependent path-
way [48]. Our results are consistent with the regulation of
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Figure 7 Effects of STAT3 pharmacologic inhibition on HASMC responses. HASMC cultures were prepared and stimulated, as previous, with
the indicated cytokines IL-4, IL-13, or IL-17A at 5 ng/ml in the absence or presence of 1 ng/ml OSM. Parallel cultures were stimulated in the
presence of either (A) 2.5 uM Stattic (black bars), (B) 10 uM SB203580 (dashed lines) or (C) 5 uM Akt X (white bars). Cell lines were stimulated
for 18 hours and cell culture supernatants were collected and assessed by ELISA for levels of MCP-1/CCL-2 (left panel) and IL-6 (right panels).
*p < 0.05; **p < 0.01, ***p < 0.001 comparing presence and absence of the indicated inhibitor in each cytokine treatment with 1 ng/ml OSM
using Two-Way ANOVA with Bonferroni’s post-test.
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upon OSM/IL-17A co-stimulation. We also observed mark-
edly high levels of eotaxin-1/CCL-11 or MCP-1/CCL-2 with
OSM/IL-4 or OSM/IL-13 stimulation (Figures 2 and 3) con-
sistent with previous work by others [36]. In contrast to pre-
vious studies on eotaxin-1/CCL-11 expression [22,48],
which were completed in serum-free conditions, in our
study here (culture conditions of 2% FBS/RPMI) we found
minimal regulation of eotaxin-1 using IL-17A alone or in
combination with OSM. Figure 6A and B shows the ana-
lysis with densitometry averaged from 3 separate cell lines,
all showing a lack of IL-17A induction of either STAT3 or
p38 in our system. To address this, we compared 2% FBS/
RPMI to serum-free conditions but observed the same
trend in our system (two different cell lines tested,Additional file 1: Figures 4C and 6C). Furthermore, IL-17A/
OSM-induced responses were clearly evident for IL-8,
MCP-1 and IL-6 in the same supernatants assessed for
eotaxin-1, and in the same samples assessed at the mRNA
level. It is not clear why our observations are not consistent
with these previous works on IL-17A (alone) induction of
STAT3 or eotaxin-1 but may relate to phenotypic differences
in the cell cultures selected by chance for our study in con-
text of the IL-17A concentrations we used. Collectively, we
suggest that the comparative role of IL-17A in eotaxin-1 ex-
pression by HASMC is less than that of IL-4 or IL-13 in the
presence of OSM.
The gp130 cytokine family members have overlapping
functions in various cells however it is also clear that
unique functions can be ascribed to individual gp130
Kwofie et al. Respiratory Research  (2015) 16:14 Page 12 of 14cytokines on the basis of differential cell signaling pathway
engagement and/or differences in cell/tissue receptor chain
expression [41,49]. In human systems, OSM can bind and
signal through either the specific OSMR complex (OSMRβ
chain and gp130 chain, termed OSMR Type II) or the LIFR
complex (LIFRα and gp130, also termed OSMR Type I).
The OSM receptor complex utilizes the OSMRβ chain
that is also a necessary chain of the IL-31 receptor
complex [31].
Since LIF did not regulate detectable HASMC cytokine
release, and low/absent STAT-3 activation, we conclude
that LIFR complex (or OSMR Type I) is minimally func-
tional in HASMC (likely due to low expression of LIFRα
subunit) and that OSM functions in HASMC are through
the specific complex OSMR Type II. IL-31 appears to have
a suppressive role in models of Th2-induced lung inflam-
mation [50] although evidence also suggests it can induce
dermatitis in animal models [51]. In our system here, IL-31
did not induce HASMC responses, suggesting its roles may
not include modulation of airway smooth muscle cells.
Previous reports have shown elevation of IL-4Rα expres-
sion in HASMC by OSM stimulation and our results con-
firm this at the mRNA level, however OSM did not induce
detectable alterations in the IL-17RA or IL-17RC receptor
chain mRNA (Figure 5). Collectively, these observations
suggest that OSM/IL-17A synergistic responses may not
involve receptor regulation, unlike that of OSM/IL-4 or
OSM/IL-13 responses. The regulation of OSM/IL-17A
responses appears to involve multiple signaling pathways,
where pharmacological STAT-3 or p38 inhibition modu-
lated MCP-1/CCL-2 and IL-6 responses. p38 inhibition
selectively modulated MCP-1/CCL-2 responses to OSM/
IL-17A stimulation and not OSM/IL-4 or OSM/IL-13
stimulation of MCP-1/CCL-2 in this system (Figure 7).
The results suggest that targeting p38 MAPK may reduce
IL-6 but not other important chemokines such as MCP-1/
CCL2, and that targeting STAT signaling may reduce
MCP-1/CCL2 in airway smooth muscle in asthma.
The OSM-induced synergy with IL-17A will likely add
to the mediation of cell responses in mixed cytokine mi-
lieus in inflammatory conditions. OSM can synergize
with IL-4/IL-13 as previously shown by others [36] who
have also shown OSM/IL-1 synergy [37]. HASMC re-
spond directly to Th2 cytokines [14] and Okada et al. [52]
suggests differential regulation of eotaxin-1 by Th1 and
Th2 cytokines. In our study here, we did not observe ac-
tivity of IFNγ nor of OSM/IFNγ combinations (Figure 2).
Thus, we speculate that OSM selectively accentuates Th2
and Th17 cytokine responses in HASMC by decreasing
the concentrations of such cytokines required to activate
these cells. This would enable higher responses to low
levels of IL-17A, IL-4 and IL-13 and thus contribute to
more marked inflammatory effects such as those seen in
severe asthma.Summary and conclusion
The regulation of cytokine/chemokine expression in
HASMC may contribute significantly to mechanisms of
pathology in asthma. MCP-1/CCL-2 interacts with CCR-
2 and has chemoattractant activity for CCR-2 positive
cells such as monocytes/T cells and in addition is
chemotactic and an activator for fibrocytes in mouse [53]
or human [11] systems. Fibrocytes, a circulating population
of CD45+ coll1+ cells that accumulate at sites of inflam-
mation, are thought to contribute to the increased
extracellular matrix in inflammatory lung conditions
including asthma [10,54,55]. OSM can enhance IL-4,
IL-13 or IL-17A induction of MCP-1/CCL-2, suggesting
multiple ways by which OSM may contribute to mono-
cyte and fibrocyte involvement in increased fibrosis seen
in severe asthmatic patients. Taken together, the synergy
of OSM with IL-4/IL-13 or IL-17A on cytokine and
chemokine production by HASMC suggests a potential
role for OSM in perpetuating airway inflammation and
remodeling. OSM activity will likely include other cell
types in vivo such as lung fibroblasts, which respond to
OSM through STAT3 mediation with functions that
promote tissue remodeling [56] .The observations that
OSM can sensitize HASMC responses to the presence
of lower concentrations of several cytokines implicated
in asthma suggest a significant contribution to the
severity of exacerbations and inflammatory pathology. It
may be particularly relevant in patients with severe
asthma who have incomplete bronchodilator reversibility
[35] given its role in modulating airway smooth muscle
biology.
Additional file
Additional file 1: Figure S1. HASMC responses to gp130 cytokines.
HASMC cultures were stimulated with 10ng/ml of LIF, IL-6, IL-31 or IL-11
and with IL-17A (0–10 ng/ml). 24-hour supernatant levels were quantified
by ELISA for MCP-1/CCL-2 (upper panel) or IL-6 (lower panel). Figure S2.
mRNA levels of Eotaxin-3. HASMC cultures were assessed for eotaxin-3
RNA (qRT-PCR) after 6 hours (top) and 18 hours (bottom) of stimulation
with the indicated cytokines at 5ng/ml (OSM at 2 ng/ml). Fold change
from control, corrected to β-Actin, is shown. Figure S3. IL-8 protein
regulation by OSM/IL-17A. HASMC cultures were stimulated with 5
ng/ml of IL-4, IL-13 or IL-17A and OSM (1 or 5 ng/ml). 18-hour supernatant
levels were quantified by ELISA. ***P<0.0001 (One-Way ANOVA) compared
to control or OSM treatment alone. Figure S4. OSM stimulation in serum
free conditions. HASMC cultures were stimulated in serum-free RPMI/1%
BSA. 24-hour supernatant levels were quantified by ELISA for (A) MCP-1 and
(B) IL-6. Panel C: HASMC cultures were stimulated with 10 ng/ml of IL-4 or
IL-17A and/or OSM in 2% FBS/RPMI or serum-free RPMI. 24-hour supernatants
were assessed by ELISA for Eotaxin-1/CCL11. *P<0.05; ***P<0.0001 compared
to control; # p<0.05 compared to either cytokine alone (One-Way ANOVA)
with Bonferroni’s post-test. Figure S5. HASMC cell signaling in serum-free
conditions. HASMC cultures from two different subjects were stimulated as
indicated (10 ng/ml) in serum-free RPMI/1% BSA for 20 minutes and lysed.
Total cell lysates were assessed for the indicated proteins by immunoblot
analysis. Figure S6. Time course of HASMC responses. HASMC cultures were
stimulated with 10 ng/ml of the indicated cytokines in 2% FBS/ RPMI (Left
panel) or serum-free RPMI/1% BSA (Right panel) for 12, 24 and 48 hours. Cell
supernatants were assessed for MCP-1 (A), IL-6 (B) and Eotaxin-1/CCL11 (C).
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